Results 271 to 280 of about 25,081,835 (313)

Natural History of Chronic Kidney Disease in Sickle Cell Disease

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1456-1477, July 2026.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin   +6 more
wiley   +1 more source

Therapeutic Potential of Berberis vulgaris in Modulating Metabolic Syndrome Biomarkers: Mechanistic Insights and Functional Food Implications

open access: yesFood Frontiers, Volume 7, Issue 4, July 2026.
ABSTRACT Barberry (Berberis vulgaris) has emerged as a promising functional food candidate for the management of metabolic syndrome due to its diverse bioactive constituents, particularly berberine. This review synthesizes current experimental and clinical evidence regarding its effects on glycemic control, lipid metabolism, blood pressure regulation ...
Fakhar Shahid   +5 more
wiley   +1 more source

Renin-Angiotensin System Autoantibody Network in Parkinson's Disease Patients. [PDF]

open access: yesAntioxidants (Basel)
Labandeira CM   +5 more
europepmc   +1 more source

Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis

open access: yesPROTEOMICS – Clinical Applications, Volume 20, Issue 4, July 2026.
ABSTRACT Background and aims Non‐alcoholic Fatty Liver Disease (NAFLD) affects about a quarter of the world's population. Liver biopsy remains the gold standard for diagnosing the progressive form of NAFLD called Non‐alcoholic Steatohepatitis (NASH) but it is invasive, prone to sampling errors and observer variability, and impractical for widespread ...
Anna Negroni   +5 more
wiley   +1 more source

Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19. [PDF]

open access: yesSci Rep
Lu A   +16 more
europepmc   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6022-6033, July 2026.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy